Menlo Park, CA — Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that it has closed its previously announced follow-on public offering of 5,175,000 shares of its common stock, including 675,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock, at a price to the public of $21.50 per share, all of which were sold by Dermira. Dermira estimates net proceeds from the offering to be approximately $104.0 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Leerink Partners LLC, Cowen and Company and Guggenheim Securities acted as joint book-running managers for the offering. Needham & Company acted as co-manager.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 5, 2015. This offering was made solely by means of a prospectus, copies of which may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by email at firstname.lastname@example.org or by telephone at 1-800-808-7525, ext. 6142; Cowen and Company, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 1-631-274-2806; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at 1-212-518-9658 or by email to GSEquityProspectusDelivery@guggenheimpartners.com.